Home » Authors » Douglas Merrill

Articles by Douglas Merrill

TeGenero Case May Prompt Tighter Clinical Trial Control

March 22, 2006

By Douglas Merrill

TeGenero Case May Prompt Tighter Clinical Trial Control

March 22, 2006

By Douglas Merrill

Vasopharm Receives EUR9.7M To Advance Head Injury Product

Feb. 1, 2006

By Douglas Merrill

Vasopharm Receives EUR9.7M To Advance Head Injury Product

Feb. 1, 2006

By Douglas Merrill

Virologist: China Hiding Size Of Avian Flu Reach, Deaths

Nov. 23, 2005

By Douglas Merrill

Virologist: China Hiding Size Of Avian Flu Reach, Deaths

Nov. 23, 2005

By Douglas Merrill

2005's Second German IPO Prices At Low End Of Range

Nov. 2, 2005

By Douglas Merrill

2005's Second German IPO Prices At Low End Of Range

Nov. 2, 2005

By Douglas Merrill

Biotechnology Focal Point In Schroeder's Re-Election Bid

June 15, 2005

By Douglas Merrill

Biotechnology Focal Point In Schroeder's Re-Election Bid

June 15, 2005

By Douglas Merrill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 3, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 3, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
Phase III AMD miss leaves BLA Outlook same with bevacizumab
BioWorld
Outlook Therapeutics Inc. is forging onward with plans to resubmit the BLA for ONS-5010, an ophthalmic version of Avastin (bevacizumab, Roche AG), after a missed...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.